Monalizumab

Innate Pharma announced AstraZeneca's interim NeoCOAST-2 Phase 2 study results at the 2024 World Conference on Lung Cancer, showing promising efficacy and safety profiles for monalizumab in early-stage NSCLC.

AstraZeneca presented interim results from the NeoCOAST-2 Phase 2 study at the 2024 World Conference on Lung Cancer, showing promising outcomes for early-stage non-small cell lung cancer patients across treatment arms. Monalizumab, in combination with durvalumab and platinum-based chemotherapy, demonstrated higher pathological complete response and major pathological response rates compared to the approved regimen, with a manageable safety profile.

The NeoCOAST-2 study showed durvalumab combined with Dato-DXd achieved the highest pathological complete response rates among tested regimens for resectable NSCLC, with Arm 4 yielding a 34.1% pCR rate and a favorable safety profile.

NeoCOAST-2 trial showed high pathologic complete response (pCR) and major pathologic response (mPR) rates in resectable NSCLC patients treated with novel combinations, with Dato-DXd plus durvalumab and single-agent platinum chemotherapy achieving the highest pCR (34.1%) and mPR (65.9%) rates. All arms demonstrated manageable safety profiles and comparable surgical rates.